Diabetes Pharmacotherapies and Bladder Cancer: A Medicare Epidemiologic Study by Mackenzie, Todd A et al.
Dartmouth College
Dartmouth Digital Commons
Open Dartmouth: Faculty Open Access Articles
2-19-2016
Diabetes Pharmacotherapies and Bladder Cancer:











Follow this and additional works at: https://digitalcommons.dartmouth.edu/facoa
Part of the Medicine and Health Sciences Commons
This Article is brought to you for free and open access by Dartmouth Digital Commons. It has been accepted for inclusion in Open Dartmouth: Faculty
Open Access Articles by an authorized administrator of Dartmouth Digital Commons. For more information, please contact
dartmouthdigitalcommons@groups.dartmouth.edu.
Recommended Citation
Mackenzie, Todd A.; Zaha, Rebecca; Smith, Jeremy; Karagas, Margaret R.; and Morden, Nancy E., "Diabetes Pharmacotherapies and
Bladder Cancer: A Medicare Epidemiologic Study" (2016). Open Dartmouth: Faculty Open Access Articles. 2781.
https://digitalcommons.dartmouth.edu/facoa/2781
ORIGINAL RESEARCH
Diabetes Pharmacotherapies and Bladder Cancer:
A Medicare Epidemiologic Study
Todd A. Mackenzie . Rebecca Zaha . Jeremy Smith . Margaret R. Karagas .
Nancy E. Morden
To view enhanced content go to www.diabetestherapy-open.com
Received: December 8, 2015 / Published online: February 19, 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
ABSTRACT
Objective: Patients with type II diabetes have
an increased risk of bladder cancer and are
commonly treated with thiazolidinediones and
angiotensin receptor blockers (ARBs), which
have been linked to cancer risk. We explored
the relationship between use of one or both of
these medication types and incident bladder
cancer among diabetic patients (diabetics)
enrolled in Medicare.
Research Design and Methods: We constructed
both a prevalent and incident retrospective
cohort of pharmacologically treated prevalent
diabetics enrolled in a Medicare fee-for-service
plan using inpatient, outpatient (2003–2011)
and prescription (2006–2011) administrative
data. The association of incident bladder
cancer with exposure to pioglitazone,
rosiglitazone and ARBs was studied using
muitivariable Cox’s hazard models with
time-dependent covariates in each of the two
cohorts.
Results: We identified 1,161,443 prevalent and
320,090 incident pharmacologically treated
diabetics, among whom 4433 and 1159,
respectively, developed incident bladder cancers.
In the prevalent cohort mean age was 75.1 years,
mean follow-up time was 38.0 months, 20.2%
filled a prescription for pioglitazone during
follow-up, 10.4% received rosiglitazone, 31.6%
received an ARB and 8.0% received combined
therapy with pioglitazone ? ARB. We found a
positive association between bladder cancer and
duration of pioglitazone use in the prevalent
cohort (P for trend = 0.008), with C24 months of
pioglitazone exposure corresponding to a 16%
(95% confidence interval 0–35%) increase in the
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incidence of bladder cancer compared to no use.
There was a positive association between bladder
cancer and rosiglitazone use for \24 months in
the prevalent cohort, but no association with ARB
use. There were no significant associations in the
incident cohort.
Conclusions: We found that the incidence of
bladder cancer increased with duration of
pioglitazone use in a prevalent cohort of
diabetics aged 65? years residing in the USA,
but not an incident cohort.




Type 2 diabetes mellitus has been associated with
an increased risk of diverse cancers [1, 2]. Bladder
cancer, the sixth most common cancer in U.S.
adults, occurs 10–40% more often in adults with
diabetes than in those without diabetes [3]. The
etiology of higher cancer incidence among
diabetic patients (diabetics) is not fully
understood [1]. Common risk factors, such as
obesity [4–6] or lack of physical activity [7], may
explain part of the increased risk. Hyperglycemia
[8, 9] and hyperinsulinemia [6, 10, 11] have been
suggested as contributing to the risk of cancer,
while the degree of glucose control does not
appear toalter the cancer risk [12]. The association
between cancer and medications commonly used
by diabetics has also been suggested to be
associated with an increased cancer risk, but this
association remains uncertain. Consequently,
medication-associated risk warrants continued
exploration given the excess cancer experienced
by this population and their relatively intense use
of pharmaceuticals.
Researchers assessing the relationship
between pharmacotherapies for the treatment
of diabetes and cancer risk have reported mixed
results. The most common hypoglycemic agent
used in the USA, metformin, may reduce the
risk of certain cancers [13–16], while
sulfonylureas do not appear to modify cancer
risk [17]. The effect of exogenous insulin on
cancer risk is unclear [18–20]. Angiotensin
receptor blockers (ARBs), which are
recommended by American Diabetes
Association guidelines as either a first choice
or alternative to angiotensin-converting
enzyme inhibitors (ACE-Is) for hypertension,
have been associated with a modest increase in
cancer risk [21]. Evidence linking the oral
hypoglycemic agent, pioglitazone, to an
increased risk of bladder cancer is mixed
[22–27]. In 2013 the International Agency for
Research on Cancer deemed pioglitazone a
possible carcinogen [28]. Less is known about
the other thiazolidinedione, rosiglitazone, also
in use in the USA [22, 26]. Very little is known
about the association of cancer with
combination pharmacotherapy among
diabetics; however, polypharmacy is common
among diabetics, raising concern for additive or
synergistic cancer-promoting or cancer-causing
effects of such medications.
To advance our understanding of the
association between bladder cancer and
pharmacotherapies for diabetics, particularly
thiazolidinediones (TZD), and the
combination of TZD with ARB therapy, we
have undertaken a retrospective cohort study
using Medicare administrative data. An
improved understanding of the relationship
between pharmacotherapies for diabetes and
bladder cancer could advance clinical care,
informing treatment selection and shared
decision-making.
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RESEARCH DESIGN AND METHODS
Prevalent and Incident Cohorts
We used a 40% random sample of the Medicare
Beneficiary Summary (denominator) file and
corresponding Medicare administrative data
from Parts A (inpatient insurance) and B
(outpatient insurance) for the period
2004–2012 and from Part D (prescription
insurance) for the period 2006–2012 to
identify patients receiving diabetes
medications [see Electronic Supplementary
Material (ESM) Table 1 for medication codes].
Patients were included in the prevalent cohort if
(1) they had filled at least one diabetes-specific
prescription between 2006 and 2012, and (2)
the prescription receipt was preceded by at least
24 months of continuous enrollment in Parts A
and B of the Medicare fee-for-service plan (to
permit ascertainment of pre-observation
co-morbidities and diabetes complications).
Patients were included in the incident cohort
if their first fill for a diabetes medication
between 2006 and 2012 was preceded by
120 days of enrollment in Part D of the
Medicare fee-for-service plan. Patients with a
prior cancer diagnoses were excluded (defined
as at least one inpatient or two outpatient
diagnoses of cancer other than non-melanoma
skin) during the 24-month look-back. Patients
aged \65, those in a hospice and those
originally entitled to Medicare enrollment due
to end-stage renal disease or disability were also
excluded. See ESM Table 2 for the list of
diagnostic codes used for exclusion.
Outcomes
The primary outcome of interest was incident
bladder cancer. This was defined as the first
inpatient or first of two outpatient diagnoses of
bladder cancer (see ESM Table 2 for ICD-9
codes) and a claim for a cytoscopy service
within 4 months before or after the first
diagnosis date.
Follow-Up and Censoring
Subjects were considered in follow-up from the
time they met the definition for entry into the
cohort until an occurrence of an initial incident
bladder cancer or until right censoring by (1)
non-incident non-bladder cancer, (2) end of
fee-for-service enrollment in Parts A, B or D of
Medicare or (3) death.
Exposures of Interest
The exposures of primary interest were
pioglitazone, rosiglitazone and ARBs. In
addition, we assessed exposure to metformin,
sulfonylureas, insulin glargine, other insulin
analogs, human insulin, and ACE-Is (see ESM
Table 1 for list) because (1) these medications
are common substitutes for the exposures of
interest and (2) their use identifies diabetics
with similar severity of illness and creates a
proxy control for diabetes severity. For each
patient we used Part D prescription fill records
to identify and quantify drug exposure in a
counting process-style format. The exposures
are time-dependent covariates defined as ever
use or duration of observed use prior to that
time.
Covariates
The following covariates were included in the
models: age, gender, race (categorized as Black,
Hispanic, and other based on the Medicare
denominator file variable), and low-income
subsidy for Medicare Part D (a marker for
income 150% or less of the federally defined
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poverty level) [29]. The following comorbidities,
diagnosed once or more at any time during the
24-month look-back were also included: alcohol
abuse, chronic obstructive lung disease and/or
tobacco use (combined as ‘‘tobacco exposure’’
proxy variable), obesity, diabetes complications
(diabetic retinopathy, nephropathy,
neuropathy, vasculopathy) and Charlson
comorbidities (see ESM Table 3) not otherwise
excluded or included [30].
Statistical Analysis
We evaluated the association of cumulative
duration of pharmacotherapy exposures in the
prevalent and incident cohorts of treated
diabetics with incidence of bladder cancer
using cause-specific hazard ratios (HR)
estimated using Cox’s proportional hazards
models for time-dependent covariates,
adjusting for the covariates listed in the
‘‘Covariates’’ section as well as calendar year.
This approach assumes that competing risks,
such as death, are independent of the occurrence
of an incident bladder cancer. The cause-specific
HR does not incorporate reduction in the
populations at risk due to competing risks as
does the sub-distribution HR [31]. We report
univariable models (one exposure at a time,
controlling for covariates) and multivariable
models (association of each exposure
controlling for other exposures and covariates).
We conducted analyses using cumulative
duration of use as a continuous variable and
separately cumulative duration categorized
using the cut-off points of 1, 12 and 24 months.
The time-scale in these models was time since
meeting the criteria for cohort entry. We tested
for proportionality of hazards using the
Schoenfeld’s residual test.
We tested the interaction of ARBs with
pioglitazone, with rosiglitazone and with other
hypoglycemics, as the product of the
cumulative durations as well as a binary
indicator of ever having used both (not
necessarily concurrently).
The Committee for the Protection of Human
Subjects at Dartmouth College approved this
study. We used data provided by Medicare and
entered a data use agreement with CMS (Center
for Medicare and Medicaid Services). Data were
stripped of personal health identifiers and are
stored behind a secure firewall.
Compliance with Ethics Guidelines
This article does not contain any new studies
with human or animal subjects performed by
any of the authors.
RESULTS
The prevalent and incident cohorts consisted of
1,161,443 and 320,090 enrollees in the
Medicare fee-for service plan filling at least
one anti-diabetic prescription, as described in
Table 1. The prevalent cohort was 62.5%
female, 10.7% black and 9.8% Hispanic. Mean
age at the beginning of follow-up was 75.9 years
in females and 73.6 years in males; 18.9% had
‘‘tobacco exposure’’ and 4.5% had more than
one diabetes complication. The median
Charlson score in both cohorts was 1
[interquartile range (IQR) 0–2]. The median
follow-up was 38.0 (IQR 19.0–67.0) months.
We identified 4433 cases of bladder cancer,
which is an incidence of 2.2/1000 person years
(PY) in men and 0.5/1000 PY in women. As
shown in Table 2, 20.1% of the cohort used
pioglitazone at least once (mean duration of use
21.1 months). Rosiglitazone was used by 10.4%
of the cohort (mean duration of use
16.5 months), ARBs by 31.6% and an ACE-I by
58.9%. A total of 8.0% of the cohort had
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exposure to both pioglitazone and ARBs, while
4.1% of the cohort had exposure to both
rosiglitazone and ARBs.
Figure 1 presents the HR relating duration of
pharmacotherapy to a subsequent diagnosis of
bladder cancer, adjusted for demographics and
other patient characteristics at baseline, but not
other pharmacotherapies. In the prevalent
diabetes cohort, duration of pioglitazone use
was associated with increased incidence of
bladder cancer (P for trend, adjusted = 0.004),
with a 16% (95% CI 0–35%) elevated risk of
bladder cancer among those using pioglitazone
for C24 months. In contrast, there was no
association between an increased risk of
bladder cancer and pioglitazone use in the
incident diabetes cohort (P[0.10). In the
prevalent cohort—but not in the incident
Table 1 Cohort characteristics of pharmacotherapeutically treated diabetic patients enrolled in Medicare between 2006 and
2012 overall and by sex




Follow-up months 42.2 (26.4) 37.3 (23.3)
Female 62.5% 62.4%




White and other 79.4% 81.3%
Low-income subsidyb 42.1% 41.7%
Obese 7.7% 7.2%
COPD/tobacco usec 18.9% 22.7%
Charlson comorbiditiesd 0.9 (1.2) 1.0 (1.3)




Data in table are presented as the mean with the standard deviation (SD) in parenthesis, or as the percentage
COPD Chronic obstructive pulmonary disease
a Patients were included in the prevalent cohort if (1) they had filled at least one diabetes-specific prescription between
2006 and 2012, and (2) the prescription receipt was preceded by at least 24 months of continuous enrollment in Parts A
and B of the Medicare fee-for-service plan. Patients were included in the incident cohort if their first fill for a diabetes
medication between 2006 and 2012 was preceded by 120 days of enrollment in Part D of the Medicare fee-for-service plan
b A dichotomous indicator of poverty equals\150% of the federal poverty level
c Chronic obstructive pulmonary disease
d Charlson Comorbidities include: human immunodeficiency virus, congestive heart failure, cerebrovascular disease,
diabetes, liver diseases, myocardial infarction, peptic ulcer disease, hemiplegia/paralysis, peripheral vascular disease, renal
disease, rheumatoid arthritis
e Diabetes complications are: renal, ophthalmologic, neurologic, circulatory, unspecified
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cohort—there was a non-monotonic association
of rosiglitazone use with bladder cancer. ARB
use was found to be unrelated to risk. In the
secondary analyses, use of sulfonylureas for
1–11 months was associated with a 17% (95%
CI 8–27%) higher risk of bladder cancer in the
prevalent cohort and an 18% (95% CI 2–37%)
higher risk in the incident cohort, but use for
[12 months was not associated with increased
risk. Metformin was associated with a
significantly lower risk of bladder cancer in the
incident cohort.
Table 3 displays the results of multivariable
models that include diabetic
pharmacotherapies as well as demographic and
comorbidity characteristics, for both the
prevalent diabetes and incident diabetes
cohorts. The monotonic association of
pioglitazone duration with bladder cancer
persisted (P for trend = 0.008) in the prevalent
cohort but was not found in the incident
cohort. The incidence of bladder cancer in
those who received pioglitazone for
C24 months was 16% higher than in those
who received none. Diabetics in the prevalent
cohort who used rosiglitazone for 1–12 and
13–24 months were at a 19% (6–35%) and 28%
(9–51%) increased risk of bladder cancer,
respectively, compared to those with no use,
while those with C24 months of pioglitazone
use had a 10% (-9 to 34%) higher risk. In
contrast, there were no significant findings in
the incident diabetes cohort. In the prevalent
cohort, duration of sulfonylurea duration had
an inconsistent association with bladder cancer
risk; similar but non-significant associations
were ascertained in the incident cohort. Any
metformin use was associated with a 17 (5–27%)
Table 2 Frequency of incident bladder cancer and exposure to diabetes medications, overall and by sex
Bladder cancer cases/diabetes medications Prevalent cohort Incident cohort
Number of bladder cancer cases 4433 (0.4%) 1159 (0.4%)
Incidence of bladder cancer (cases/1000 PY) 1.08 1.16
Pioglitazone use (N) 20.1% (233,450) 11.9% (38,091)
Mean exposure, months (SD) 21.1 (31.8) 16.6 (27.7)
Rosiglitazone use (N) 10.4% (120,790) 4.8% (15,364)
Mean exposure, months (SD) 16.5 (17.6) 11.2 (14.2)
ARB use (N) 31.6% (367,016) 28.6% (91,546)
Mean exposure, months (SD) 24.5 (25.5) 20.8 (22.0)
ACE-I use (N) 58.9% (684,090) 53.0% (169,648)
Mean exposure, months (SD) 28.1 (37.6) 22.2 (30.7)
Metformin use (N) 61.1% (709,642) 61.4% (196,535)
Mean exposure, months (SD) 58.3 (59.7) 37.5 (42.8)
Sulfonylurea use (N) 51.8% (601,627) 39.6% (126,756)
Mean exposure, months (SD) 29.1 (23.4) 22.1 (20.1)
Data are presented as the number (of enrollees) with the percentage in parenthesis, as the percentage with the number (of
enrollees) in parenthesis or as the mean with the SD in parenthesis
PY Person-years, ARB angiotensin II receptor blocker, ACE-I angiotensin converting enzyme inhibitors
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lower risk in the incident cohort but not a
significantly lower risk in the prevalent cohort.
We evaluated the effect of exposure to
combined pharmacotherapy with pioglitazone
? ARB but found that the interaction was not
significant (P = 0.37), nor was there any
significant (P[0.05) association of bladder
cancer with pairwise interactions of any of the
diabetes medications.
DISCUSSION
Using a Medicare cohort of over 1 million U.S.
pharmacologically treated diabetic patients
aged C67 years, we found that the incidence
of bladder cancer increased with duration of
pioglitazone use in the prevalent diabetes
cohort but not in the incident diabetes one.
We also found an association of increased
incidence of bladder cancer with duration of
rosiglitazone use in the prevalent cohort, but it
was non-monotonic, and the association was
not present in the incident diabetes cohort. The
use of metformin was associated with a decrease
in bladder cancer incidence among incident
diabetics. Finally, the use of an ARB and the
combined therapy with an ARB ? TZD was
unrelated to bladder cancer incidence.
Fig. 1 For each of the pharmacotherapies, hazard ratios
for bladder cancer occurrence are shown with 95%
confidence intervals for duration of use categorized as
1–12, 13–24 and[24 months versus no previous use.
Each hazard ratio is adjusted for age, gender, year, race/
ethnicity, low income, number of diabetes complications
and chronic obstructive pulmonary disease/tobacco use.
ARB Angiotensin receptor blocker, ACE-I an-
giotensin-converting enzyme inhibitors
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Table 3 Hazard ratios for incident bladder cancer versus medication duration of use from the multivariable model: the
multivariable model includes all variables in this table
Model variables Prevalent cohort Incident cohort
Hazard ratio 95% Confidence
interval




1–12 months 1.03 0.93 1.14 0.521 1.02 0.81 1.28 0.8845
13–24 months 1.14 0.98 1.31 0.091 0.95 0.62 1.44 0.8054
[24 months 1.16 1.00 1.35 0.044 1.24 0.83 1.84 0.2969
Rosiglitazone
1–12 months 1.19 1.06 1.35 0.004 1.13 0.83 1.53 0.4490
13–24 months 1.28 1.09 1.51 0.002 1.21 0.70 2.09 0.5011
[24 months 1.10 0.91 1.34 0.314 0.93 0.41 2.08 0.8535
Sulfonylurea
1–12 months 1.15 1.07 1.25 0.000 1.14 0.98 1.32 0.0962
13–24 months 0.92 0.83 1.01 0.081 0.97 0.79 1.20 0.7920
[24 months 0.84 0.77 0.92 0.000 0.88 0.72 1.07 0.2064
ARB 1.02 0.95 1.10 0.495 1.05 0.91 1.21 0.4789
ACE-I 1.06 0.99 1.13 0.087 1.01 0.89 1.14 0.9093
Insulin glargine 1.00 0.91 1.10 0.994 0.99 0.79 1.26 0.9655
Human insulin 0.90 0.82 1.00 0.049 0.99 0.79 1.24 0.9372
Other analog insulin 1.01 0.91 1.12 0.852 0.66 0.51 0.87 0.0032
Metformin 0.96 0.90 1.02 0.186 0.83 0.73 0.95 0.0060
Age (years)a
70–74 1.38 1.27 1.51 0.000 1.21 1.01 1.45 0.0375
75–79 1.75 1.60 1.91 0.000 1.41 1.17 1.70 0.0003
80–84 1.81 1.64 1.99 0.000 1.81 1.49 2.20 0.0000
85? 1.93 1.72 2.16 0.000 1.87 1.50 2.33 0.0000
Year 1.01 0.99 1.03 0.384 1.00 0.96 1.03 0.8086
Racea
Black 0.63 0.55 0.72 0.000 0.59 0.44 0.79 0.0004
Hispanic 0.57 0.49 0.65 0.000 0.60 0.46 0.78 0.0001
Female 0.25 0.23 0.26 0.000 0.22 0.19 0.25 0.0000
Low income 0.74 0.69 0.79 0.000 0.74 0.65 0.86 0.0000
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The TZD, pioglitazone, has been labeled a
‘‘probable carcinogen’’ by the International
Agency for Research on Cancer (IARC) [28].
Several meta-analyses have found it to be
associated with an increased risk of cancer
[22–24, 32–34]. We also found pioglitazone
use to be associated with an increased risk of
bladder cancer. Our relative risk estimate of 1.16
in the prevalent diabetes cohort and 1.24 in the
incident diabetes cohort for C24 months of
pioglitazone exposure among prevalent
diabetics is similar to the value of 1.2 found in
a recent meta-analysis of observational studies,
but much less than that of 2.5 reported in a
meta-analysis of randomized studies [33]. It is
possible that our estimate from the prevalent
cohort is biased toward the null due to
measurement error of the duration of use as a
result of unknown treatment histories before
the implementation of Part D in 2006 and
before patients reached the age of Medicare
benefits. Our null finding in the incident cohort
may be due to reduced power compared to the
prevalent cohort; we did find that individuals
with C24 months of pioglitazone use had 24%
more incident bladder cancers, but this
difference was not statistically significant.
Rosiglitazone, the other TZD used in the
USA, has been evaluated for its association with
bladder cancer in meta-analyses [22, 23, 32–34]
and none, including the most recent
meta-analysis, detected an association. In the
IARC assessment [28], rosiglitazone was
unclassifiable with respect to its bladder
carcinogenicity. However, an animal study
found that it promoted bladder tumor growth
[35]. In the prevalent diabetes cohort,
rosiglitazone use for [24 months was not
associated with an increased risk of bladder
cancer, but we did observe a 19% increased risk
among those who used this drug for
1–12 months and a 28% increased risk among
those using it for 13–23 months. This
non-monotonic association is at most weak
evidence of an association, or it indicates an
unusual mechanism. The association of
rosiglitazone and bladder cancer therefore
requires further study.
In secondary analyses, we found metformin
use was associated with a reduction in the
development of bladder cancer in the incident
diabetes cohort. Other studies have also
reported that metformin is associated with
lower cancer incidence [13, 14]. In a
claims-based cohort study from Taiwan,
patients receiving metformin were at lower
risk of bladder cancer [36], and a UK cohort
study also found evidence of lower bladder
cancer risk, but the results of the latter study
were not statistically significant [37]. We
Table 3 continued
Model variables Prevalent cohort Incident cohort
Hazard ratio 95% Confidence
interval
P value Hazard ratio 95 Confidence
interval
P value
No. of diabetes complicationsa
2 0.99 0.84 1.17 0.917 1.62 1.15 2.30 0.0060
C3 0.77 0.52 1.13 0.181 0.76 0.28 2.04 0.5910
COPD/tobacco use 1.48 1.38 1.59 0.000 1.40 1.23 1.60 0.0000
a Referent groups were (1) Age:\70 years; Race: White; No. of diabetes complications: 0–1
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examined bladder cancer risk associated with
sulfonylureas, another common class of
anti-diabetic drugs. A recent meta-analysis
reported a 55% increased risk of cancer among
sulfonylurea users based on cohort studies, but
no association based on data from either
randomized or case–control studies [38]. In the
prevalent diabetes cohort, we found an
increased risk for low to moderate duration of
use but a decreased risk for use of [2 years.
Thus, the relationship between this class of
anti-diabetics and bladder cancer remains
unclear.
Most diabetes patients receive an ACE-I or ARB
in addition to glucose-lowering therapy. A
meta-analysis [39] found the use of ARBs to be
associated with a 10% increase in bladder cancer,
although a meta-analysis restricted to randomized
studies found no difference in risk [40]. We found
no association between ARB use and bladder
cancer in our two study cohorts. Moreover, we
examined the possibility that exposure to a
combination of pioglitazone ? ARBs or
rosiglitazone ? ARBs increased bladder cancer risk
beyond that expected based on their main effects,
but did not find evidence of an interaction.
Our study has several limitations
characteristic of claims-based analyses. We
lacked information on potential confounders,
such as body mass index, physical activity,
family history of cancer and environmental
exposure. Our measure of tobacco use and past
tobacco exposure depended on diagnosis codes.
While clinicians are improving their tendency
to explicitly diagnose tobacco use, we likely
underestimated this important risk factor.
Similarly, the diagnosis of chronic obstructive
pulmonary disease itself may be incomplete,
and even when made likely reflects a broad
range of disease and past/current tobacco use.
Our co-morbidity assignments and cancer
events depend on the coding accuracy in these
data sets. Previous studies have found that
Medicare administrative data can identify
cancer cases with good specificity (C98%) and
acceptable sensitivity (83–90%) [41]. In our
analysis, we used a 24-month look-back period
to identify prevalent cancer cases, and we
assumed that patients with no cancer
diagnosis during this period to be cancer free.
Some recurrent cancer cases could have been
misclassified as incident. Our measurement of
duration of treatment and cumulative exposure
in the prevalent cohort is truncated at entry
into the cohort; we have no records of
prescription fills preceding Part D enrollment
or preceding the age of 65 years when Medicare
benefits begin for elderly beneficiaries. The
effect of this measurement error is likely to be
non-differential, resulting in estimates biased
toward the null. Our definition of an incident
cohort is debatable; we define a diabetic as
incident if we did not observe them to have a
prescription for a diabetes medication for at
least 4 months. Furthermore, our list of
prescriptions for diabetes medications did not
include the newer although less commonly
prescribed diabetes drugs (such as GLP-1,
DPP-IV, acarbose and glinides). We rely on the
dose dispensed, which is an imperfect measure
of dose consumed. Prescription fill records have
been shown to be a good proxy measure of
prescription use, but poor adherence also could
result in misclassification of exposure that
would bias our findings toward the null [42].
Finally, our findings do not necessarily
generalize to individuals with diabetes younger
than 65 years of age.
CONCLUSION
In conclusion, our findings are consistent with
those of previous studies revealing a modest
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elevation in the incidence of bladder cancer
associated with pioglitazone use. Associations
with rosiglitazone were less clear, and no
relation with bladder cancer was detected for
the use of ARBs or ARBs combined with either of
the TZDs. Clinicians and prescription benefits
managers should consider prioritizing
alternatives to pioglitazone, when possible,
and engaging in shared decision-making when
pioglitazone is prescribed. Attention should be
paid to the benefits of glycemic control relative
to the small but measurable increased risk in
bladder cancers. Patients at higher risk of
bladder cancer due to other factors (e.g.
smoking, male gender, family history or
environmental exposures) may warrant more
thorough decision-making before initiating
pioglitazone and perhaps rosiglitazone.
ACKNOWLEDGMENTS
Funding and support. National Institutes of
Health: National Cancer Institute
1R03CA167723-01A1. No funding or support
was received for the publication of this article.
All named authors meet the International
Committee of Medical Journal Editors (ICMJE)
criteria for authorship for this manuscript, take
responsibility for the integrity of the work as a
whole and have given final approval for the
version to be published.
Author contributions. MK, NM and TM
conceived the study. JS, RZ, NM and TM
developed the analytic dataset. JS conducted
the analysis. NM and TM guided the statistical
analysis. NM, RZ and TM wrote the manuscript.
JS and MK reviewed/edited the manuscript.
Disclosures. The authors declare that they
have no conflict of interests to report.
Compliance with Ethics Guidelines. This
article does not contain any new studies with
human or animal subjects performed by any of
the authors.
Open Access. This article is distributed
under the terms of the Creative Commons
Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/
by-nc/4.0/), which permits any noncommer-
cial use, distribution, and reproduction in any
medium, provided you give appropriate credit
to the original author(s) and the source, provide
a link to the Creative Commons license, and
indicate if changes were made.
REFERENCES
1. Harding JL, Shaw JE, Peeters A, Cartensen B,
Magliano DJ. Cancer risk among people with type
1 and type 2 diabetes: disentangling true
associations, detection bias, and reverse causation.
Diabetes Care. 2015;38:264–70.
2. Giovannucci E, Harlan DM, Archer MC, et al.
Diabetes and cancer: a consensus report. Diabetes
Care. 2010;33:1674–85.
3. Larsson SC, Orsini N, Brismar K, Wolk A. Diabetes
mellitus and risk of bladder cancer: a meta-analysis.
Diabetologia. 2006;49:2819–23.
4. Garg SK, Maurer H, Reed K, Selagamsetty R.
Diabetes and cancer: two diseases with obesity as
a common risk factor. Diabetes Obes Metab.
2014;16:97–110.
5. Qin Q, Xu X, Wang X, Zheng XY. Obesity and risk
of bladder cancer: a meta-analysis of cohort studies.
Asian Pac J Cancer Prev. 2013;14:3117–21.
6. Westley RL, May FE. A twenty-first century cancer
epidemic caused by obesity: the involvement of
insulin, diabetes, and insulin-like growth factors.
Int J Endocrinol. 2013;2013:632461.
7. Keimling M, Behrens G, Schmid D, Jochem C,
Leitzmann MF. The association between physical
activity and bladder cancer: systematic review and
meta-analysis. Br J Cancer. 2014;110:1862–70.
Diabetes Ther (2016) 7:61–73 71
8. Ryu TY, Park J, Scherer PE. Hyperglycemia as a risk
factor for cancer progression. Diabetes Metab J.
2014;38:330–6.
9. Stattin P, Bjor O, Ferrari P, et al. Prospective study of
hyperglycemia and cancer risk. Diabetes Care.
2007;30:561–7.
10. Novosyadlyy R, LeRoith D. Hyperinsulinemia and
type 2 diabetes: impact on cancer. Cell Cycle.
2010;9:1449–50.
11. Dankner R, Shanik MH, Keinan-Boker L, Cohen C,
Chetrit A. Effect of elevated basal insulin on cancer
incidence and mortality in cancer incident patients:
the Israel GOH 29-year follow-up study. Diabetes
Care. 2012;35:1538–43.
12. Johnson JA, Bowker SL. Intensive glycaemic control
and cancer risk in type 2 diabetes: a meta-analysis of
major trials. Diabetologia. 2011;54:25–31.
13. Gandini S, Puntoni M, Heckman-Stoddard BM,
et al. Metformin and cancer risk and mortality: a
systematic review and meta-analysis taking into
account biases and confounders. Cancer Prevent
Res. 2014;7:867–85.
14. Franciosi M, Lucisano G, Lapice E, Strippoli GF,
Pellegrini F, Nicolucci A. Metformin therapy and
risk of cancer in patients with type 2 diabetes:
systematic review. PLoS ONE. 2013;8:e71583.
15. Aldea M, Craciun L, Tomuleasa C, et al.
Repositioning metformin in cancer: genetics, drug
targets, and new ways of delivery. Tumour Biol.
2014;35:5101–10.
16. Pernicova I, Korbonits M. Metformin-mode of
action and clinical implications for diabetes and
cancer. Nat Rev Endocrinol. 2014;10:143–56.
17. Soranna D, Scotti L, Zambon A, et al. Cancer risk
associated with use of metformin and sulfonylurea
in type 2 diabetes: a meta-analysis. Oncologist.
2012;17:813–22.
18. Karlstad O, Starup-Linde J, Vestergaard P, et al. Use
of insulin and insulin analogs and risk of cancer—
systematic review and meta-analysis of
observational studies. Curr Drug Saf.
2013;8:333–48.
19. Colmers IN, Bowker SL, Tjosvold LA, Johnson JA.
Insulin use and cancer risk in patients with type 2
diabetes: a systematic review and meta-analysis of
observational studies. Diabetes Metab.
2012;38:485–506.
20. Morden Nancy E, Liu Stephen K, Smith J,
Mackenzie TA, Skinner J, Korc M. Further
exploration of the relationship between insulin
glargine and incident cancer: a retrospective cohort
study of older medicare patients. Diabetes Care.
2011;34:1965–71.
21. Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang
JC. Angiotensin-receptor blockade and risk of
cancer: meta-analysis of randomised controlled
trials. Lancet Oncol. 2010;11:627–36.
22. Colmers IN, Bowker SL, Majumdar SR, Johnson JA.
Use of thiazolidinediones and the risk of bladder
cancer among people with type 2 diabetes: a
meta-analysis. CMAJ. 2012;184:E675–83.
23. He S, Tang YH, Zhao G, Yang X, Wang D, Zhang Y.
Pioglitazone prescription increases risk of bladder
cancer in patients with type 2 diabetes: an updated
meta-analysis. Tumour Biol. 2014;35:2095–102.
24. Ferwana M, Firwana B, Hasan R, et al. Pioglitazone
and risk of bladder cancer: a meta-analysis of
controlled studies. Diabet Med. 2013;30:1026–32.
25. Zhu Z, Shen Z, Lu Y, Zhong S, Xu C. Increased risk
of bladder cancer with pioglitazone therapy in
patients with diabetes: a meta-analysis. Diabetes
Res Clin Pract. 2012;98:159–63.
26. Levin D, Bell S, Sund R, et al. Pioglitazone and
bladder cancer risk: a multipopulation pooled,
cumulative exposure analysis. Diabetologia.
2015;58:493–504.
27. Lewis JD, Habel LA, Quesenberry CP, et al.
Pioglitazone use and risk of bladder cancer and
other common cancers in persons with diabetes.
JAMA. 2015;314:265–77.
28. Grosse Y, Loomis D, Lauby-Secretan B, et al.
Carcinogenicity of some drugs and herbal
products. Lancet Oncol. 2013;14:807–8.
29. US Department of Health and Human Resources.
Creation of new race–ethnicity codes and
socioeconomic status (SES) indicators for Medicare
beneficiaries. 2008. Available at: http://www.ahrq.
gov/qual/medicareindicators/medicareindicators2.
htm. Accessed 23 Apr 2010.
30. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A
new method of classifying prognostic comorbidity
in longitudinal studies: development and
validation. J Chronic Dis. 1987;40:373–83.
31. Wolbers M, Koller MT, Stel VS, et al. Competing
risks analyses: objectives and approaches. Eur Heart
J. 2014;35:2936–41.
32. Bosetti C, Rosato V, Buniato D, Zambon A, La
Vecchia C, Corrao G. Cancer risk for patients using
thiazolidinediones for type 2 diabetes: a
meta-analysis. Oncologist. 2013;18:148–56.
72 Diabetes Ther (2016) 7:61–73
33. Turner RM, Kwok CS, Chen-Turner C, Maduakor
CA, Singh S, Loke YK. Thiazolidinediones and
associated risk of bladder cancer: a systematic
review and meta-analysis. Br J Clin Pharmacol.
2014;78:258–73.
34. Monami M, Dicembrini I, Mannucci E.
Thiazolidinediones and cancer: results of a
meta-analysis of randomized clinical trials. Acta
Diabetol. 2014;51:91–101.
35. Lubet RA, Fischer SM, Steele VE, Juliana MM,
Desmond R, Grubbs CJ. Rosiglitazone, a PPAR
gamma agonist: potent promoter of
hydroxybutyl(butyl)nitrosamine-induced urinary
bladder cancers. Int J Cancer. 2008;123:2254–9.
36. Tseng CH. Metformin may reduce bladder cancer
risk in Taiwanese patients with type 2 diabetes. Acta
Diabetol. 2014;51:295–303.
37. Mamtani R, Pfanzelter N, Haynes K, et al. Incidence
of bladder cancer in patients with type 2 diabetes
treated with metformin or sulfonylureas. Diabetes
Care. 2014;37:1910–7.
38. Thakkar B, Aronis KN, Vamvini MT, Shields K,
Mantzoros CS. Metformin and sulfonylureas in
relation to cancer risk in type II diabetes patients:
a meta-analysis using primary data of published
studies. Metab Clin Exp. 2013;62:922–34.
39. Hallas J, Christensen R, Andersen M, Friis S,
Bjerrum L. Long term use of drugs affecting the
renin–angiotensin system and the risk of cancer: a
population-based case-control study. Br J Clin
Pharmacol. 2012;74:180–8.
40. Collaboration ARBT. Effects of telmisartan,
irbesartan, valsartan, candesartan, and losartan on
cancers in 15 trials enrolling 138,769 individuals.
J Hypertens. 2011;29:623–35.
41. Setoguchi S, Solomon DH, Glynn RJ, Cook EF,
Levin R, Schneeweiss S. Agreement of diagnosis and
its date for hematologic malignancies and solid
tumors between medicare claims and cancer
registry data. Cancer Causes Control.
2007;18:561–9.
42. Lau HS, de Boer A, Beuning KS, Porsius A.
Validation of pharmacy records in drug exposure
assessment. J Clin Epidemiol. 1997;50:619–25.
Diabetes Ther (2016) 7:61–73 73
